Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash-to-Debt 0.21
NAS:OMCL's Cash-to-Debt is ranked lower than
92% of the 2082 Companies
in the Global Health Information Services industry.

( Industry Median: 8.37 vs. NAS:OMCL: 0.21 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:OMCL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: No Debt Max: No Debt
Current: 0.21
0.04
No Debt
Equity-to-Asset 0.55
NAS:OMCL's Equity-to-Asset is ranked lower than
59% of the 1985 Companies
in the Global Health Information Services industry.

( Industry Median: 0.60 vs. NAS:OMCL: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:OMCL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.57  Med: 0.66 Max: 0.78
Current: 0.55
-0.57
0.78
Debt-to-Equity 0.36
NAS:OMCL's Debt-to-Equity is ranked lower than
62% of the 1133 Companies
in the Global Health Information Services industry.

( Industry Median: 0.27 vs. NAS:OMCL: 0.36 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:OMCL' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.43  Med: 0.06 Max: 0.59
Current: 0.36
-0.43
0.59
Debt-to-EBITDA 2.78
NAS:OMCL's Debt-to-EBITDA is ranked lower than
78% of the 1031 Companies
in the Global Health Information Services industry.

( Industry Median: 1.33 vs. NAS:OMCL: 2.78 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:OMCL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.78  Med: 3.79 Max: 3.92
Current: 2.78
2.78
3.92
Interest Coverage 3.33
NAS:OMCL's Interest Coverage is ranked lower than
97% of the 1570 Companies
in the Global Health Information Services industry.

( Industry Median: 140.00 vs. NAS:OMCL: 3.33 )
Ranked among companies with meaningful Interest Coverage only.
NAS:OMCL' s Interest Coverage Range Over the Past 10 Years
Min: 0.77  Med: 196.96 Max: 2680.5
Current: 3.33
0.77
2680.5
Piotroski F-Score: 7
Altman Z-Score: 3.79
Beneish M-Score: -1.99
WACC vs ROIC
2.98%
7.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating Margin % 3.16
NAS:OMCL's Operating Margin % is ranked lower than
63% of the 2027 Companies
in the Global Health Information Services industry.

( Industry Median: 4.54 vs. NAS:OMCL: 3.16 )
Ranked among companies with meaningful Operating Margin % only.
NAS:OMCL' s Operating Margin % Range Over the Past 10 Years
Min: 0.8  Med: 6.75 Max: 11.25
Current: 3.16
0.8
11.25
Net Margin % 4.55
NAS:OMCL's Net Margin % is ranked lower than
52% of the 2027 Companies
in the Global Health Information Services industry.

( Industry Median: 3.36 vs. NAS:OMCL: 4.55 )
Ranked among companies with meaningful Net Margin % only.
NAS:OMCL' s Net Margin % Range Over the Past 10 Years
Min: 0.09  Med: 4.64 Max: 6.92
Current: 4.55
0.09
6.92
ROE % 6.95
NAS:OMCL's ROE % is ranked lower than
55% of the 1969 Companies
in the Global Health Information Services industry.

( Industry Median: 6.14 vs. NAS:OMCL: 6.95 )
Ranked among companies with meaningful ROE % only.
NAS:OMCL' s ROE % Range Over the Past 10 Years
Min: 0.14  Med: 4.78 Max: 8.26
Current: 6.95
0.14
8.26
ROA % 3.58
NAS:OMCL's ROA % is ranked lower than
53% of the 2097 Companies
in the Global Health Information Services industry.

( Industry Median: 3.01 vs. NAS:OMCL: 3.58 )
Ranked among companies with meaningful ROA % only.
NAS:OMCL' s ROA % Range Over the Past 10 Years
Min: 0.08  Med: 3.47 Max: 5.8
Current: 3.58
0.08
5.8
ROC (Joel Greenblatt) % 16.46
NAS:OMCL's ROC (Joel Greenblatt) % is ranked lower than
62% of the 2065 Companies
in the Global Health Information Services industry.

( Industry Median: 20.86 vs. NAS:OMCL: 16.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:OMCL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.43  Med: 41.98 Max: 64.63
Current: 16.46
2.43
64.63
3-Year Revenue Growth Rate 15.40
NAS:OMCL's 3-Year Revenue Growth Rate is ranked higher than
75% of the 1648 Companies
in the Global Health Information Services industry.

( Industry Median: 5.80 vs. NAS:OMCL: 15.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:OMCL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53.3  Med: 11.3 Max: 20.9
Current: 15.4
-53.3
20.9
3-Year EBITDA Growth Rate -8.10
NAS:OMCL's 3-Year EBITDA Growth Rate is ranked lower than
76% of the 1481 Companies
in the Global Health Information Services industry.

( Industry Median: 8.80 vs. NAS:OMCL: -8.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:OMCL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.5 Max: 130.8
Current: -8.1
0
130.8
3-Year EPS without NRI Growth Rate -13.90
NAS:OMCL's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 1387 Companies
in the Global Health Information Services industry.

( Industry Median: 9.80 vs. NAS:OMCL: -13.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:OMCL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -7.6 Max: 260.9
Current: -13.9
0
260.9
GuruFocus has detected 6 Warning Signs with Omnicell Inc NAS:OMCL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:OMCL's 30-Y Financials

Financials (Next Earnings Date: 2018-07-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income
» NAS:OMCL's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades
Q2 2017

OMCL Guru Trades in Q2 2017

Joel Greenblatt 33,566 sh (New)
Ken Fisher 492,202 sh (-0.02%)
Mariko Gordon 1,353,369 sh (-12.00%)
» More
Q3 2017

OMCL Guru Trades in Q3 2017

Ken Fisher 528,919 sh (+7.46%)
Mariko Gordon 1,216,632 sh (-10.10%)
Joel Greenblatt 4,705 sh (-85.98%)
» More
Q4 2017

OMCL Guru Trades in Q4 2017

Ken Fisher 530,569 sh (+0.31%)
Joel Greenblatt Sold Out
Mariko Gordon 970,386 sh (-20.24%)
» More
Q1 2018

OMCL Guru Trades in Q1 2018

Mariko Gordon Sold Out
Ken Fisher 450,562 sh (-15.08%)
» More
» Details

Insider Trades

Financial Reports

Latest Guru Trades with OMCL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-03-31 Reduce -15.08%$40.1 - $52.45 $ 52.4514%450,562
Mariko Gordon 2018-03-31 Sold Out 2.94%$40.1 - $52.45 $ 52.4514%0
Mariko Gordon 2017-12-31 Reduce -20.24%0.78%$45.3 - $54.5 $ 52.454%970,386
Ken Fisher 2017-12-31 Add 0.31%$45.3 - $54.5 $ 52.454%530,569
Joel Greenblatt 2017-12-31 Sold Out $45.3 - $54.5 $ 52.454%0
Mariko Gordon 2017-09-30 Reduce -10.10%0.35%$42.25 - $52.15 $ 52.4510%1,216,632
Ken Fisher 2017-09-30 Add 7.46%$42.25 - $52.15 $ 52.4510%528,919
Joel Greenblatt 2017-09-30 Reduce -85.98%0.02%$42.25 - $52.15 $ 52.4510%4,705
Mariko Gordon 2017-06-30 Reduce -12.00%0.44%$39.55 - $44.4 $ 52.4526%1,353,369
Ken Fisher 2017-06-30 Reduce -0.02%$39.55 - $44.4 $ 52.4526%492,202
Joel Greenblatt 2017-06-30 New Buy0.02%$39.55 - $44.4 $ 52.4526%33,566
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Application Software » Health Information Services    NAICS: 621999    SIC: 8099
Compare:NAS:INOV, NAS:PINC, HKSE:02666, SZSE:300451, NYSE:EVH, NAS:QSII, XTER:COP, NAS:TRHC, NAS:RCM, NAS:HSTM, NYSE:TDOC, LSE:EMIS, LSE:CRW, ASX:PME, SZSE:300550, XPAR:CGM, TSE:3902, SHSE:603990, TSE:4820, NAS:CPSI » details
Traded in other countries:OC9.Germany,
Headquarter Location:USA
Omnicell Inc provides automation and business analytics software solutions for patient-centric medication and supplies management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing.

Omnicell provides automation and business analytics software for healthcare providers. The firm operates in two segments: automation and analytics and medication adherence. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. This segment contributes the majority of revenue. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.

Top Ranked Articles about Omnicell Inc

STOMPP Study Demonstrates Multimed Packaging Improves Medication Adherence
June 12, 2018
Read more...
Omnicell to Showcase Industry-Leading Medication Management Automation Platform at Annual ASHP Summer Meeting
May 31, 2018
Read more...
Report: Developing Opportunities within Opexa Therapeutics, Federated National Holding, Hess Midstream Partners LP, Zion Oil & Gas, Omnicell, and Gladstone Land — Future Expectations, Projections Moving into 2018
May 24, 2018
Read more...
Mariko Gordon Closes Positions in Red Robin, Natus Medical Guru's largest sales of the 1st quarter
May 23, 2018
Mariko Gordon (Trades, Portfolio), founder of Daruma Capital Management, sold shares of the following stocks during the first quarter. Read more...
Sentara RMH Medical Center Partners with Omnicell to Enhance Efficiency, Safety in Central Pharmacy Operations
May 10, 2018
Read more...
Omnicell to Release First Quarter 2018 Earnings Results on April 26, 2018
April 19, 2018
Read more...
Omnicell Appoints Scott Seidelmann as Chief Commercial Officer
April 9, 2018
Read more...
Recent Analysis Shows Jack Henry & Associates, Omnicell, Surgery Partners, Floor & Decor, NVE, and RA PHARMCTL INC Market Influences — Renewed Outlook, Key Drivers of Growth
April 2, 2018
Read more...
Mercyhealth Adopts Omnicell's XR2 Automated Central Pharmacy System to Enhance Patient Safety
March 27, 2018
Read more...
Omnicell To Present At Needham & Company's 17th Annual Healthcare Conference
March 22, 2018
Read more...

Ratios

vs
industry		 vs
history
PE Ratio 59.61
OMCL's PE Ratio is ranked lower than
86% of the 1288 Companies
in the Global Health Information Services industry.

( Industry Median: 27.61 vs. OMCL: 59.61 )
Ranked among companies with meaningful PE Ratio only.
OMCL' s PE Ratio Range Over the Past 10 Years
Min: 8.9  Med: 41.81 Max: 1930
Current: 59.61
8.9
1930
Forward PE Ratio 26.32
OMCL's Forward PE Ratio is ranked higher than
53% of the 318 Companies
in the Global Health Information Services industry.

( Industry Median: 24.04 vs. OMCL: 26.32 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 59.61
OMCL's PE Ratio without NRI is ranked lower than
86% of the 1279 Companies
in the Global Health Information Services industry.

( Industry Median: 27.94 vs. OMCL: 59.61 )
Ranked among companies with meaningful PE Ratio without NRI only.
OMCL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.9  Med: 41.81 Max: 1930
Current: 59.61
8.9
1930
PB Ratio 3.53
OMCL's PB Ratio is ranked higher than
50% of the 1923 Companies
in the Global Health Information Services industry.

( Industry Median: 3.25 vs. OMCL: 3.53 )
Ranked among companies with meaningful PB Ratio only.
OMCL' s PB Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.36 Max: 4.33
Current: 3.53
0.96
4.33
PS Ratio 2.81
OMCL's PS Ratio is ranked higher than
51% of the 1917 Companies
in the Global Health Information Services industry.

( Industry Median: 2.57 vs. OMCL: 2.81 )
Ranked among companies with meaningful PS Ratio only.
OMCL' s PS Ratio Range Over the Past 10 Years
Min: 0.94  Med: 2.16 Max: 4.69
Current: 2.81
0.94
4.69
Price-to-Operating-Cash-Flow 136.94
OMCL's Price-to-Operating-Cash-Flow is ranked lower than
87% of the 889 Companies
in the Global Health Information Services industry.

( Industry Median: 20.00 vs. OMCL: 136.94 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
OMCL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 20.32 Max: 10100
Current: 136.94
6.98
10100
EV-to-EBIT 93.28
OMCL's EV-to-EBIT is ranked lower than
98% of the 1329 Companies
in the Global Health Information Services industry.

( Industry Median: 20.79 vs. OMCL: 93.28 )
Ranked among companies with meaningful EV-to-EBIT only.
OMCL' s EV-to-EBIT Range Over the Past 10 Years
Min: -241.1  Med: 23.4 Max: 378.3
Current: 93.28
-241.1
378.3
EV-to-EBITDA 29.37
OMCL's EV-to-EBITDA is ranked lower than
74% of the 1441 Companies
in the Global Health Information Services industry.

( Industry Median: 16.23 vs. OMCL: 29.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
OMCL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.7  Med: 15.75 Max: 52.1
Current: 29.37
3.7
52.1
EV-to-Revenue 2.96
OMCL's EV-to-Revenue is ranked lower than
51% of the 2002 Companies
in the Global Health Information Services industry.

( Industry Median: 2.59 vs. OMCL: 2.96 )
Ranked among companies with meaningful EV-to-Revenue only.
OMCL' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 2 Max: 4.3
Current: 2.96
0.4
4.3
PEG Ratio 12.57
OMCL's PEG Ratio is ranked lower than
92% of the 603 Companies
in the Global Health Information Services industry.

( Industry Median: 2.18 vs. OMCL: 12.57 )
Ranked among companies with meaningful PEG Ratio only.
OMCL' s PEG Ratio Range Over the Past 10 Years
Min: 0.5  Med: 2.32 Max: 358.8
Current: 12.57
0.5
358.8
Shiller PE Ratio 117.22
OMCL's Shiller PE Ratio is ranked lower than
83% of the 359 Companies
in the Global Health Information Services industry.

( Industry Median: 39.15 vs. OMCL: 117.22 )
Ranked among companies with meaningful Shiller PE Ratio only.
OMCL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 36.8  Med: 58.34 Max: 124.53
Current: 117.22
36.8
124.53
Current Ratio 1.68
OMCL's Current Ratio is ranked lower than
56% of the 1912 Companies
in the Global Health Information Services industry.

( Industry Median: 1.96 vs. OMCL: 1.68 )
Ranked among companies with meaningful Current Ratio only.
OMCL' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.3 Max: 5.21
Current: 1.68
0.64
5.21
Quick Ratio 1.22
OMCL's Quick Ratio is ranked lower than
68% of the 1912 Companies
in the Global Health Information Services industry.

( Industry Median: 1.81 vs. OMCL: 1.22 )
Ranked among companies with meaningful Quick Ratio only.
OMCL' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 2 Max: 4.95
Current: 1.22
0.4
4.95
Days Inventory 80.18
OMCL's Days Inventory is ranked lower than
81% of the 1183 Companies
in the Global Health Information Services industry.

( Industry Median: 17.94 vs. OMCL: 80.18 )
Ranked among companies with meaningful Days Inventory only.
OMCL' s Days Inventory Range Over the Past 10 Years
Min: 35.45  Med: 55.69 Max: 80.18
Current: 80.18
35.45
80.18
Days Sales Outstanding 93.02
OMCL's Days Sales Outstanding is ranked lower than
70% of the 1642 Companies
in the Global Health Information Services industry.

( Industry Median: 68.90 vs. OMCL: 93.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMCL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.2  Med: 69.97 Max: 96.44
Current: 93.02
56.2
96.44
Days Payable 33.88
OMCL's Days Payable is ranked higher than
50% of the 1444 Companies
in the Global Health Information Services industry.

( Industry Median: 45.06 vs. OMCL: 33.88 )
Ranked among companies with meaningful Days Payable only.
OMCL' s Days Payable Range Over the Past 10 Years
Min: 26.08  Med: 35.76 Max: 50.91
Current: 33.88
26.08
50.91

Buy Back

vs
industry		 vs
history
3-Year Average Share Buyback Ratio -2.40
OMCL's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 1376 Companies
in the Global Health Information Services industry.

( Industry Median: -3.20 vs. OMCL: -2.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OMCL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -140.8  Med: -2.6 Max: 1.6
Current: -2.4
-140.8
1.6

Valuation & Return

vs
industry		 vs
history
Price-to-Tangible-Book 63.96
OMCL's Price-to-Tangible-Book is ranked lower than
99.99% of the 1612 Companies
in the Global Health Information Services industry.

( Industry Median: 4.78 vs. OMCL: 63.96 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OMCL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.2  Med: 5.37 Max: 63.96
Current: 63.96
1.2
63.96
Price-to-Intrinsic-Value-Projected-FCF 2.31
OMCL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
52% of the 789 Companies
in the Global Health Information Services industry.

( Industry Median: 2.28 vs. OMCL: 2.31 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OMCL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.94  Med: 1.46 Max: 12.74
Current: 2.31
0.94
12.74
Price-to-Intrinsic-Value-DCF (Earnings Based) 5.57
OMCL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
99.99% of the 129 Companies
in the Global Health Information Services industry.

( Industry Median: 1.82 vs. OMCL: 5.57 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
OMCL' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 3.3  Med: 4.1 Max: 161.43
Current: 5.57
3.3
161.43
Price-to-Median-PS-Value 1.30
OMCL's Price-to-Median-PS-Value is ranked higher than
51% of the 1595 Companies
in the Global Health Information Services industry.

( Industry Median: 1.14 vs. OMCL: 1.30 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OMCL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.06 Max: 2.27
Current: 1.3
0.23
2.27
Price-to-Graham-Number 12.98
OMCL's Price-to-Graham-Number is ranked lower than
99.99% of the 920 Companies
in the Global Health Information Services industry.

( Industry Median: 2.64 vs. OMCL: 12.98 )
Ranked among companies with meaningful Price-to-Graham-Number only.
OMCL' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.33  Med: 3.02 Max: 12.98
Current: 12.98
1.33
12.98
Earnings Yield (Greenblatt) % 1.07
OMCL's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 2098 Companies
in the Global Health Information Services industry.

( Industry Median: 1.99 vs. OMCL: 1.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OMCL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.8  Med: 3.9 Max: 19
Current: 1.07
-0.8
19
Forward Rate of Return (Yacktman) % 0.60
OMCL's Forward Rate of Return (Yacktman) % is ranked lower than
73% of the 834 Companies
in the Global Health Information Services industry.

( Industry Median: 10.67 vs. OMCL: 0.60 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
OMCL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.6  Med: 21.6 Max: 25
Current: 0.6
0.6
25

More Statistics

Revenue (TTM) (Mil) $748.23
EPS (TTM) $ 0.88
Beta0.72
Volatility24.54%
52-Week Range $39.75 - 55.40
Shares Outstanding (Mil)38.88

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 792 875 965
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 0.96 1.40 2.17
EPS without NRI ($) 0.96 1.40 2.17
EPS Growth Rate
(Future 3Y To 5Y Estimate)		 2.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

» More Articles for OMCL

Headlines

Articles On GuruFocus.com
STOMPP Study Demonstrates Multimed Packaging Improves Medication Adherence Jun 12 2018 
Omnicell to Showcase Industry-Leading Medication Management Automation Platform at Annual ASHP Summe May 31 2018 
Report: Developing Opportunities within Opexa Therapeutics, Federated National Holding, Hess Midstre May 24 2018 
Mariko Gordon Closes Positions in Red Robin, Natus Medical May 23 2018 
Sentara RMH Medical Center Partners with Omnicell to Enhance Efficiency, Safety in Central Pharmacy May 10 2018 
Omnicell to Release First Quarter 2018 Earnings Results on April 26, 2018 Apr 19 2018 
Omnicell Appoints Scott Seidelmann as Chief Commercial Officer Apr 09 2018 
Recent Analysis Shows Jack Henry & Associates, Omnicell, Surgery Partners, Floor & Decor, NVE, and R Apr 02 2018 
Mercyhealth Adopts Omnicell's XR2 Automated Central Pharmacy System to Enhance Patient Safety Mar 27 2018 
Omnicell To Present At Needham & Company's 17th Annual Healthcare Conference Mar 22 2018 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}